{{Rsnum
|rsid=179997
|Gene=ATXN1
|Chromosome=6
|position=16318402
|Orientation=minus
|GMAF=0.2401
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=ATXN1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 36.9 | 43.1 | 20.0
| HCB | 71.1 | 22.2 | 6.7
| JPT | 77.8 | 22.2 | 0.0
| YRI | 98.4 | 1.6 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 71.1 | 22.2 | 6.7
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs179997
|Name_s=DRD2: A-241G
|Gene_s=ATXN1
|Feature=
|Evidence=PubMed ID:17105675
|Annotation=Phenotype: In a study population treated for 8 weeks with risperidone the patients with the A allele of the A-241G SNP showed greater improvement than those with the G allele on the overall Brief Psychiatric Rating Scale (chi2=7.19, p=0.00, p=0.031 after correction by the program SNPSpD). Study size: 125. Study population: Chinese.
|Drugs=risperidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291674
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs179997
|overall_frequency_n=29
|overall_frequency_d=128
|overall_frequency=0.226562
|n_genomes=23
|n_genomes_annotated=0
|n_haplomes=31
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}